NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 11:17AM ET
203.72
Dollar change
+6.18
Percentage change
3.13
%
IndexS&P 500 P/E39.50 EPS (ttm)5.16 Insider Own8.87% Shs Outstand715.60M Perf Week3.16%
Market Cap145.80B Forward P/E23.77 EPS next Y8.57 Insider Trans-1.96% Shs Float652.19M Perf Month7.28%
Enterprise Value161.39B PEG4.79 EPS next Q1.64 Inst Own81.60% Short Float1.19% Perf Quarter-0.62%
Income3.77B P/S6.12 EPS this Y2.97% Inst Trans0.49% Short Ratio1.84 Perf Half Y-11.92%
Sales23.82B P/B2.87 EPS next Y11.27% ROA4.63% Short Interest7.75M Perf YTD-11.25%
Book/sh71.06 P/C73.15 EPS next 5Y8.24% ROE7.22% 52W High281.70 -27.68% Perf Year-19.08%
Cash/sh2.78 P/FCF29.74 EPS past 3/5Y-15.01% 9.03% ROIC5.63% 52W Low171.00 19.13% Perf 3Y-10.51%
Dividend Est.1.21 (0.60%) EV/EBITDA21.47 Sales past 3/5Y-6.76% 5.92% Gross Margin59.80% Volatility2.40% 2.23% Perf 5Y34.04%
Dividend TTM1.18 (0.58%) EV/Sales6.78 EPS Y/Y TTM-12.75% Oper. Margin21.67% ATR (14)5.03 Perf 10Y253.75%
Dividend Ex-DateJun 27, 2025 Quick Ratio1.05 Sales Y/Y TTM-9.19% Profit Margin15.81% RSI (14)59.31 Recom1.31
Dividend Gr. 3/5Y8.74% 9.69% Current Ratio1.43 EPS Q/Q-8.94% SMA202.64% Beta0.77 Target Price245.55
Payout20.42% Debt/Eq0.35 Sales Q/Q-0.95% SMA504.31% Rel Volume0.50 Prev Close197.54
Employees63000 LT Debt/Eq0.31 EarningsJul 22 BMO SMA200-8.68% Avg Volume4.21M Price203.72
IPODec 10, 1969 Option/ShortYes / Yes EPS/Sales Surpr.15.52% 3.04% Trades Volume656,731 Change3.13%
Date Action Analyst Rating Change Price Target Change
Apr-10-25Upgrade Barclays Equal Weight → Overweight $205
Mar-21-25Upgrade Goldman Neutral → Buy $260
Mar-14-25Upgrade Stifel Hold → Buy $260
Feb-03-25Downgrade Raymond James Outperform → Mkt Perform
Dec-23-24Initiated Scotiabank Sector Perform
Dec-19-24Initiated Guggenheim Buy $275
Dec-13-24Upgrade BofA Securities Neutral → Buy $290
Oct-31-24Upgrade Wolfe Research Peer Perform → Outperform $285
Oct-01-24Initiated Stephens Overweight $315
Aug-28-24Initiated Wells Fargo Equal Weight $280
Today 09:50AM
Jun-30-25 11:34AM
01:09AM
Jun-28-25 12:20PM
Jun-27-25 11:40AM
07:35AM Loading…
07:35AM
07:30AM
Jun-25-25 09:01PM
12:27PM
12:23PM
10:47AM
Jun-24-25 11:52AM
Jun-20-25 09:45AM
Jun-17-25 04:30PM
12:10PM
04:31PM Loading…
Jun-13-25 04:31PM
Jun-11-25 11:40AM
02:00AM
Jun-05-25 12:02AM
Jun-02-25 07:00AM
07:00AM
07:00AM
May-30-25 11:50AM
10:12AM
May-29-25 11:11PM
04:30PM
May-26-25 11:40AM
May-22-25 04:40PM
11:30AM
09:54AM
04:09PM Loading…
May-21-25 04:09PM
May-15-25 07:15PM
01:00PM
May-09-25 05:25PM
11:40AM
06:32AM
12:33AM
May-08-25 05:58PM
May-07-25 04:15PM
01:25PM
04:55AM
May-06-25 04:15PM
May-02-25 09:30AM
04:00AM
May-01-25 02:26PM
Apr-30-25 10:15AM
Apr-29-25 11:30AM
10:07AM
08:25AM
Apr-28-25 08:16AM
Apr-27-25 02:22PM
03:01AM
Apr-25-25 08:03PM
Apr-24-25 04:54AM
Apr-23-25 05:30PM
12:10PM
11:40AM
03:01AM
Apr-22-25 10:30PM
09:35PM
09:35PM
04:05PM
02:22PM
12:14PM
11:09AM
10:00AM
09:30AM
09:28AM
09:28AM
07:10AM
06:17AM
06:07AM
06:00AM
Apr-21-25 10:16AM
08:04AM
Apr-19-25 01:25AM
Apr-16-25 09:15AM
Apr-15-25 01:49PM
10:00AM
Apr-13-25 05:41PM
Apr-11-25 08:28AM
03:20AM
Apr-10-25 01:30PM
11:44AM
Apr-08-25 02:22PM
Apr-07-25 07:28PM
12:50PM
Apr-04-25 09:06PM
11:57AM
09:25AM
Apr-03-25 07:51AM
Apr-02-25 07:30AM
12:10AM
Apr-01-25 04:59PM
04:55PM
Mar-31-25 10:24PM
04:35AM
02:27AM
Mar-30-25 11:19PM
09:05AM
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RALES STEVEN MChairmanMay 12 '25Sale196.741,250,000245,919,3913,105,808May 14 05:19 PM
RALES STEVEN MOfficerMay 12 '25Proposed Sale194.821,250,000243,525,000May 12 09:30 PM
Raskas DanielFormer OfficerMay 02 '25Proposed Sale201.037,0531,417,865May 02 10:45 AM
Riley Christopher PaulExecutive Vice PresidentApr 30 '25Option Exercise76.477,801596,54230,984May 01 05:01 PM
Riley Christopher PaulExecutive Vice PresidentApr 30 '25Sale198.0015,8053,129,42415,179May 01 05:01 PM
Riley Christopher PaulOfficerApr 30 '25Proposed Sale198.0015,8053,129,421Apr 30 03:41 PM
Glenstone FoundationSee RemarksApr 24 '25Proposed Sale196.50598,281117,562,216Apr 24 05:28 PM
King WilliamFormer OfficerMar 11 '25Proposed Sale207.1464,69713,401,340Mar 11 04:03 PM
King WilliamOfficerFeb 21 '25Proposed Sale209.97114,35124,010,531Feb 21 04:18 PM
Sabeti Pardis Cformer Board of DirectorsFeb 18 '25Proposed Sale204.284,337885,953Feb 18 01:04 PM
SPOON ALAN GDirectorFeb 07 '25Option Exercise59.343,928233,088121,068Feb 10 05:00 PM
SPOON ALAN GDirectorFeb 07 '25Sale206.46550113,553120,518Feb 10 05:00 PM
SPOON ALAN GDirectorFeb 07 '25Proposed Sale206.46550113,553Feb 07 03:34 PM
Ellis Brian WSenior Vice President - GCJan 30 '25Option Exercise58.595,700333,96325,930Jan 31 05:00 PM
Ellis Brian WSenior Vice President - GCJan 30 '25Sale224.135,7001,277,54120,230Jan 31 05:00 PM
Ellis Brian WOfficerJan 30 '25Proposed Sale224.135,7001,277,542Jan 30 12:56 PM
Raskas DanielSVP - Corporate DevelopmentNov 26 '24Option Exercise58.5926,3181,541,97241,543Nov 27 05:01 PM
Raskas DanielSVP - Corporate DevelopmentNov 26 '24Sale236.5926,3186,226,49715,225Nov 27 05:01 PM
Raskas DanielSVP - Corporate DevelopmentNov 25 '24Sale238.008,3701,992,06015,225Nov 27 05:01 PM
Raskas DanielOfficerNov 26 '24Proposed Sale236.5926,3186,226,496Nov 26 04:40 PM
Raskas DanielOfficerNov 25 '24Proposed Sale238.008,3701,992,060Nov 25 12:04 PM
Glenstone FoundationSee RemarksNov 05 '24Proposed Sale247.76100,00024,776,000Nov 05 04:01 PM
Weidemanis JoakimFormer DirectorOct 23 '24Proposed Sale254.9517,6594,502,216Oct 23 01:10 PM
Couchara GeorgeannSVP, Human ResourcesAug 26 '24Sale268.37952255,4834,212Aug 27 05:04 PM
Couchara GeorgeannOfficerAug 26 '24Proposed Sale268.37952255,483Aug 26 04:40 PM
Glenstone FoundationSee RemarksAug 13 '24Proposed Sale267.2047,93712,808,766Aug 13 04:05 PM
Blair RainerPresident & CEOJul 31 '24Sale280.009,0072,521,96097,983Aug 02 05:00 PM
FILLER LINDADirectorAug 01 '24Option Exercise59.343,928233,08845,077Aug 02 05:00 PM
FILLER LINDADirectorAug 01 '24Sale279.503,9281,097,87641,149Aug 02 05:00 PM
McGrew MatthewEVP & Chief Financial OfficerAug 01 '24Option Exercise62.8516,1721,016,41045,579Aug 02 05:00 PM
McGrew MatthewEVP & Chief Financial OfficerAug 01 '24Sale279.8416,1724,525,55529,407Aug 02 05:00 PM
McGrew MatthewOfficerAug 01 '24Proposed Sale279.8416,1724,525,555Aug 01 04:28 PM
FILLER LINDADirectorAug 01 '24Proposed Sale279.503,9281,097,876Aug 01 12:27 PM
Blair RainerOfficerJul 31 '24Proposed Sale280.009,0072,521,960Jul 31 04:26 PM
Ellis Brian WSenior Vice President - GCJul 25 '24Sale275.169,6002,641,53620,230Jul 26 05:03 PM
Raskas DanielSVP - Corporate DevelopmentJul 25 '24Sale270.5114,5073,924,35223,595Jul 26 05:03 PM
Zerhouni Elias A.DirectorJul 15 '24Option Exercise52.563,289172,87037,483Jul 16 05:01 PM
SCHWIETERS JOHN TDirectorJul 15 '24Option Exercise52.563,289172,87019,808Jul 16 05:00 PM